|Bid||0.0000 x 1000|
|Ask||0.0000 x 800|
|Day's Range||2.9200 - 3.2300|
|52 Week Range||0.9500 - 8.5700|
|Beta (3Y Monthly)||2.96|
|PE Ratio (TTM)||10.29|
|Earnings Date||Feb 23, 2018 - Mar 5, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.00|
As some employees raised concerns about MiMedx’s practices, Petit directed an internal effort dubbed “Project Snow White” to find ways to undermine them, rather than look into the merits of their complaints, the company said. Current contact information for two other former executives faulted by the company -- Chief Financial Officer Michael Senken and Controller John Cranston -- couldn’t be found.
MiMedx Group Inc (OTC: MDXG) can't seem to leave controversy behind. MiMedx, which sells injectable wound care products, was testing the finished products quarterly as opposed to checking each lot, WSJ said, citing an internal document prepared for the company in January by Lachman Consultants. The biomedical product company sells wound care products derived from the amniotic sac that protects the fetus, processing it into patches or grinding it into a powder.
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs May 23.) ArQule, Inc. (NASDAQ: ARQL ) Turning Point ...
MiMedx Group Inc. said late Thursday an internal investigation revealed that now-former executives spied on employees to discredit whistleblowers. The wound-care products company's stock was delisted from the Nasdaq in November after the company's chief executive and chief operating officer resigned in July during an internal audit. Late Thursday, the company said the audit uncovered 2,750 hours of video footage from a secret surveillance system installed under orders of Parker Petit, the company's former chairman and CEO. The audit found that Petit, former COO William Taylor, former Chief Financial Officer Michael Senken, and former Controller John Cranston knew about revenue manipulation practices related to deals with its largest distributor. The company also said Petit and Taylor launched an internal investigation named "Project Snow White," which included secret surveillance, to root out potential whistleblowers and employees who were concerned about the company's practices.
MARIETTA, Ga., May 23, 2019 /PRNewswire/ -- MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or "the Company"), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced that the Audit Committee of the Board of Directors has concluded its independent investigation ("the Investigation") into matters relating to, among other things, allegations regarding certain sales and distribution practices at the Company. As announced on February 20, 2018, the Audit Committee retained King & Spalding LLP as counsel to assist the Audit Committee in conducting its Investigation.
Prescience Point Capital Management cut its holding of the regenerative biomaterials maker to 7,618,335 shares on April 29 through May 3. During that span, Prescience acquired 250,000 shares for $2.31 to $2.51 each and sold 603,925 at prices ranging from $2.44 to $2.53 apiece. Prescience now owns nearly 7% of MiMedx’s outstanding stock.
Healthcare Industry Veteran to Lead Next Phase of MiMedx MARIETTA, Ga. , May 9, 2019 /PRNewswire/ -- MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or "the Company"), an industry leader ...
For help, it turned to a friendly senator in Washington, Johnny Isakson. After the VA said it would no longer purchase medical tissue sold by MiMedx Group Inc., Isakson made at least three phone calls to the agency on behalf of his friend and the company’s chief executive officer, Parker H. Petit, according to two officials who spoke with the senator. One of those officials recounted trying to assuage the senator by explaining that it was an across-the-board policy.
BATON ROUGE, La., May 7, 2019 /PRNewswire/ -- Prescience Point Capital Management, LLC, a private investment management firm, together with certain investment partnerships under its management (collectively, "Prescience Point"), today announced that it has nominated a slate of four world-class candidates for election to the MiMedx Group, Inc. ("MiMedx" or the "Company") (MDXG) Board of Directors (the "Board") at the Company's upcoming Annual Meeting of Shareholders (the "Annual Meeting"), scheduled to be held on June 17, 2019. Prescience Point, together with its director nominees, owns approximately 9.98% of the common stock of MiMedx.
MARIETTA, Ga., April 11, 2019 /PRNewswire/ -- MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or "the Company"), an industry leader in advanced wound care and an emerging therapeutic biologics company, today reinforced its priorities for 2019 as part of its long-range strategic plan to enhance value for all MiMedx stakeholders.
NEW YORK, NY / ACCESSWIRE / December 12, 2018 / U.S. equities finished lower on Tuesday after bouncing between the red and green territory. The stocks gained more than 1% across the board on improving ...
MARIETTA, Ga., Dec. 5, 2018 /PRNewswire/ -- MiMedx Group, Inc. (OTC PINK: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced that on December 4, 2018, Ernst & Young LLP informed the Company's Audit Committee that it has resigned from the engagement to audit the Company's financial statements for the years ended December 31, 2017 and 2018, effective immediately. MiMedx® is a leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The Company processes the human placental tissue utilizing its proprietary PURION® process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization.
MARIETTA, Ga., Dec. 5, 2018 /PRNewswire/ -- MiMedx Group, Inc. (OTC PINK: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced certain leadership changes and promotions in conjunction with its plans to implement a broad-based organizational realignment program designed to position the business for long-term success. Additional details regarding the program are available in the Company's press release issued earlier today. "As we continue our efforts to transform our business, we are focused on ensuring that we have the right team and organizational structure in place.
MARIETTA, Ga., Dec. 5, 2018 /PRNewswire/ -- MiMedx Group, Inc. (OTC PINK: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced its plans to implement a broad-based organizational realignment, cost reduction and efficiency program to better ensure the Company's cost structure is appropriate given its revenue expectations. MiMedx plans to execute these initiatives while continuing to deliver products and support for healthcare providers and the patients they serve. "Today's announcement is a continuation of management's efforts to position the business for long-term success by focusing on our wound care business, where our clinical studies best support patient outcomes and for which reimbursement policy has traditionally been more stable," said David Coles, Interim Chief Executive Officer.
New market trends are pushing investors to pay closer attention to the healthcare industry as it has been seen as a safe haven during turbulent times in the broader markets. In fact, according to the "Cognitive Computing and Artificial Intelligence Systems Market in Healthcare" report from ResearchAndMarkets these technologies have gained significant traction. Increased adoption of cognitive and AI platforms can be attributed to their wide application potential across the healthcare industry, including patients and hospitals.
NEW YORK, NY / ACCESSWIRE / November 8, 2018 / U.S. markets advanced on Wednesday as the midterm election results went according to market expectations. The Democrats took over the House, while the Republicans ...
NEW YORK , Nov. 7, 2018 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600: S&P MidCap 400 constituent Jack Henry & Associates Inc. ...